{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:23:34Z","timestamp":1790785414600,"version":"4.1.0"},"reference-count":174,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002857","name":"China Pharmaceutical University","doi-asserted-by":"publisher","award":["81530098"],"award-info":[{"award-number":["81530098"]}],"id":[{"id":"10.13039\/501100002857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81530098"],"award-info":[{"award-number":["81530098"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["81530098"],"award-info":[{"award-number":["81530098"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["81530098"],"award-info":[{"award-number":["81530098"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.pharmthera.2021.107867","type":"journal-article","created":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T18:16:27Z","timestamp":1619115387000},"page":"107867","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"special_numbering":"C","title":["The pathophysiological function of non-gastrointestinal farnesoid X receptor"],"prefix":"10.1016","volume":"226","author":[{"given":"Nana","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangliu","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiping","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangji","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank J.","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2021.107867_bb0005","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41575-020-00406-0","article-title":"Nonalcoholic fatty liver disease: another leap forward","volume":"18","author":"Abdelmalek","year":"2021","journal-title":"Nature Reviews. Gastroenterology & Hepatology"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0010","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12974-017-0833-6","article-title":"Activation of FXR pathway does not alter glial cell function","volume":"14","author":"Albrecht","year":"2017","journal-title":"Journal of Neuroinflammation"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0015","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.celrep.2013.10.030","article-title":"Bile acids activate YAP to promote liver carcinogenesis","volume":"5","author":"Anakk","year":"2013","journal-title":"Cell Reports"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0020","doi-asserted-by":"crossref","first-page":"28857","DOI":"10.1074\/jbc.M011610200","article-title":"Human bile salt export pump promoter is transactivated by the farnesoid X receptor\/bile acid receptor","volume":"276","author":"Ananthanarayanan","year":"2001","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0025","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1002\/hep.26710","article-title":"Glucose sensing O-GlcNAcylation pathway regulates the nuclear bile acid receptor farnesoid X receptor (FXR)","volume":"59","author":"Berrabah","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0030","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1172\/JCI129401","article-title":"Bile acid metabolism is altered in multiple sclerosis and supplementation ameliorates neuroinflammation","volume":"130","author":"Bhargava","year":"2020","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0035","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1073\/pnas.0400046101","article-title":"Expression and activation of the farnesoid X receptor in the vasculature","volume":"101","author":"Bishop-Bailey","year":"2004","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0040","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.1210\/en.2015-1321","article-title":"Bile acids trigger GLP-1 release predominantly by accessing basolaterally located G protein-coupled bile acid receptors","volume":"156","author":"Brighton","year":"2015","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0045","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1136\/gut.18.9.692","article-title":"Serum, cerebrospinal fluid, and brain levels of bile acids in patients with fulminant hepatic failure","volume":"18","author":"Bron","year":"1977","journal-title":"Gut"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0050","doi-asserted-by":"crossref","first-page":"8732","DOI":"10.1074\/jbc.RA119.008360","article-title":"Phosphorylation of hepatic farnesoid X receptor by FGF19 signaling-activated Src maintains cholesterol levels and protects from atherosclerosis","volume":"294","author":"Byun","year":"2019","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0055","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1038\/s41467-018-04697-5","article-title":"Postprandial FGF19-induced phosphorylation by Src is critical for FXR function in bile acid homeostasis","volume":"9","author":"Byun","year":"2018","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0060","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41586-020-2193-0","article-title":"Bacterial metabolism of bile acids promotes generation of peripheral regulatory T cells","volume":"581","author":"Campbell","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0065","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S1262-3636(08)74605-6","article-title":"The farnesoid X receptor (FXR) as a new target in non-alcoholic steatohepatitis","volume":"34","author":"Cariou","year":"2008","journal-title":"Diabetes & Metabolism"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0070","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41589-020-0604-z","article-title":"Bariatric surgery reveals a gut-restricted TGR5 agonist with anti-diabetic effects","volume":"17","author":"Chaudhari","year":"2021","journal-title":"Nature Chemical Biology"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0075","doi-asserted-by":"crossref","first-page":"9335","DOI":"10.12659\/MSM.920065","article-title":"Farnesoid X Receptor (FXR) aggravates amyloid-beta-triggered apoptosis by modulating the cAMP-response element-binding protein (CREB)\/brain-derived neurotrophic factor (BDNF) pathway in vitro","volume":"25","author":"Chen","year":"2019","journal-title":"Medical Science Monitor"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0080","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.psychres.2018.04.025","article-title":"Hippocampal FXR plays a role in the pathogenesis of depression: A preliminary study based on lentiviral gene modulation","volume":"264","author":"Chen","year":"2018","journal-title":"Psychiatric Research"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0085","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1002\/hep.26187","article-title":"Bile salt export pump is dysregulated with altered farnesoid X receptor isoform expression in patients with hepatocellular carcinoma","volume":"57","author":"Chen","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0090","doi-asserted-by":"crossref","first-page":"10918","DOI":"10.1074\/jbc.275.15.10918","article-title":"Farnesoid X receptor responds to bile acids and represses cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription","volume":"275","author":"Chiang","year":"2000","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0095","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21207750","article-title":"The status of bile acids and farnesoid X receptor in brain and liver of rats with thioacetamide-induced acute liver failure","volume":"21","author":"Czarnecka","year":"2020","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0100","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nrneph.2016.75","article-title":"Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis","volume":"12","author":"D\u2019Agati","year":"2016","journal-title":"Nature Reviews Nephrology"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0105","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1053\/gast.2001.25503","article-title":"The orphan nuclear receptor, shp, mediates bile acid-induced inhibition of the rat bile acid transporter, ntcp","volume":"121","author":"Denson","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0110","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.apsb.2015.01.004","article-title":"Bile acid nuclear receptor FXR and digestive system diseases","volume":"5","author":"Ding","year":"2015","journal-title":"Acta Pharmaceutica Sinica B"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0115","doi-asserted-by":"crossref","first-page":"890","DOI":"10.2337\/diabetes.53.4.890","article-title":"Glucose regulates the expression of the farnesoid X receptor in liver","volume":"53","author":"Duran-Sandoval","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0120","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jhep.2020.07.048","article-title":"miR-552-3p modulates transcriptional activities of FXR and LXR to ameliorate hepatic glycolipid metabolism disorder","volume":"74","author":"Fan","year":"2021","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0125","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nm.3760","article-title":"Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance","volume":"21","author":"Fang","year":"2015","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0130","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.2353\/ajpath.2009.090114","article-title":"Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts","volume":"175","author":"Fickert","year":"2009","journal-title":"The American Journal of Pathology"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0135","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1053\/j.gastro.2004.08.001","article-title":"The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis","volume":"127","author":"Fiorucci","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0140","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.coph.2020.04.008","article-title":"Bile acid-activated receptors and the regulation of macrophages function in metabolic disorders","volume":"53","author":"Fiorucci","year":"2020","journal-title":"Current Opinion in Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0145","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.3389\/fimmu.2018.01853","article-title":"Bile acids activated receptors regulate innate immunity","volume":"9","author":"Fiorucci","year":"2018","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0150","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1124\/jpet.105.085597","article-title":"Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis","volume":"315","author":"Fiorucci","year":"2005","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0155","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/toxsci\/kfaa111","article-title":"Regulation of lung macrophage activation and oxidative stress following ozone exposure by farnesoid X receptor","volume":"177","author":"Francis","year":"2020","journal-title":"Toxicological Sciences"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0160","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s11745-017-4242-5","article-title":"Ursodeoxycholic acid suppresses lipogenesis in mouse liver: possible role of the decrease in \u03b2-muricholic acid, a farnesoid X receptor antagonist","volume":"52","author":"Fujita","year":"2017","journal-title":"Lipids"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0165","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.bbalip.2014.08.005","article-title":"Tissue-specific actions of FXR in metabolism and cancer","volume":"1851","author":"Gadaleta","year":"2015","journal-title":"Biochimica et Biophysica Acta"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0170","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1194\/jlr.D028803","article-title":"Targeted profiling of circulating and hepatic bile acids in human, mouse, and rat using a UPLC-MRM-MS-validated method","volume":"53","author":"Garcia-Canaveras","year":"2012","journal-title":"Journal of Lipid Research"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0175","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.jhep.2019.05.030","article-title":"Liver infiltrating T cells regulate bile acid metabolism in experimental cholangitis","volume":"71","author":"Glaser","year":"2019","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0180","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1053\/j.gastro.2016.08.057","article-title":"An intestinal microbiota-farnesoid X receptor axis modulates metabolic disease","volume":"151","author":"Gonzalez","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0185","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1159\/000450908","article-title":"Intestinal farnesoid X receptor signaling modulates metabolic disease","volume":"35","author":"Gonzalez","year":"2017","journal-title":"Digestive Diseases"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0190","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S1097-2765(00)00051-4","article-title":"A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis","volume":"6","author":"Goodwin","year":"2000","journal-title":"Molecular Cell"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0195","doi-asserted-by":"crossref","first-page":"8157","DOI":"10.1038\/s41598-018-26383-8","article-title":"Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis","volume":"8","author":"Goto","year":"2018","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0200","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/bph.14570","article-title":"Betulinic acid alleviates endoplasmic reticulum stress-mediated nonalcoholic fatty liver disease through activation of farnesoid X receptors in mice","volume":"176","author":"Gu","year":"2019","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0205","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41575-019-0226-7","article-title":"Primary biliary cholangitis: Pathogenesis and therapeutic opportunities","volume":"17","author":"Gulamhusein","year":"2020","journal-title":"Nature Reviews Gastroenterology & Hepatology"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0210","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.immuni.2016.09.008","article-title":"Bile acids control inflammation and metabolic disorder through inhibition of NLRP3 inflammasome","volume":"45","author":"Guo","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0215","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.bbalip.2006.09.018","article-title":"Effects of FXR in foam-cell formation and atherosclerosis development","volume":"1761","author":"Guo","year":"2006","journal-title":"Biochimica et Biophysica Acta"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0220","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1016\/j.celrep.2018.07.068","article-title":"FXR inhibits endoplasmic reticulum stress-induced NLRP3 inflammasome in hepatocytes and ameliorates liver injury","volume":"24","author":"Han","year":"2018","journal-title":"Cell Reports"},{"issue":"856\u2013867","key":"10.1016\/j.pharmthera.2021.107867_bb0225","article-title":"Farnesoid X receptor regulation of the NLRP3 inflammasome underlies cholestasis-associated sepsis","volume":"25","author":"Hao","year":"2017","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0230","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1161\/01.RES.0000200400.55539.85","article-title":"Downregulation of endothelin-1 by farnesoid X receptor in vascular endothelial cells","volume":"98","author":"He","year":"2006","journal-title":"Circulation Research"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0235","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.steroids.2017.07.001","article-title":"Unconjugated bile acids in rat brain: Analytical method based on LC\/ESI-MS\/MS with chemical derivatization and estimation of their origin by comparison to serum levels","volume":"125","author":"Higashi","year":"2017","journal-title":"Steroids"},{"issue":"751\u2013761","key":"10.1016\/j.pharmthera.2021.107867_bb0240","article-title":"Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid","volume":"148","author":"Hirschfield","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0245","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1073\/pnas.1524890113","article-title":"Obeticholic acid, a synthetic bile acid agonist of the farnesoid X receptor, attenuates experimental autoimmune encephalomyelitis","volume":"113","author":"Ho","year":"2016","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0250","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1002\/1873-3468.12373","article-title":"Identification of functional farnesoid X receptors in brain neurons","volume":"590","author":"Huang","year":"2016","journal-title":"FEBS Letters"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0255","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3389\/fnbeh.2015.00070","article-title":"Deletion of mouse FXR gene disturbs multiple neurotransmitter systems and alters neurobehavior","volume":"9","author":"Huang","year":"2015","journal-title":"Frontiers in Behavioral Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0260","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00401-016-1593-6","article-title":"The farnesoid-X-receptor in myeloid cells controls CNS autoimmunity in an IL-10-dependent fashion","volume":"132","author":"Hucke","year":"2016","journal-title":"Acta Neuropathologica"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0265","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.jhep.2016.01.016","article-title":"Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid","volume":"64","author":"Ijssennagger","year":"2016","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0270","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/hep4.1256","article-title":"FXR and TGR5 agonists ameliorate liver injury, steatosis, and inflammation after binge or prolonged alcohol feeding in mice","volume":"2","author":"Iracheta-Vellve","year":"2018","journal-title":"Hepatology Communications"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0275","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nrgastro.2017.119","article-title":"Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis","volume":"15","author":"Jia","year":"2018","journal-title":"Nature Reviews Gastroenterology & Hepatology"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0280","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1111\/febs.15204","article-title":"Conditional loss of geranylgeranyl diphosphate synthase alleviates acute obstructive cholestatic liver injury by regulating hepatic bile acid metabolism","volume":"287","author":"Jia","year":"2020","journal-title":"FEBS Letters"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0285","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1172\/JCI76738","article-title":"Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease","volume":"125","author":"Jiang","year":"2015","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0290","doi-asserted-by":"crossref","first-page":"10166","DOI":"10.1038\/ncomms10166","article-title":"Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction","volume":"6","author":"Jiang","year":"2015","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0295","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.2337\/db06-1642","article-title":"Farnesoid X receptor modulates renal lipid metabolism, fibrosis, and diabetic nephropathy","volume":"56","author":"Jiang","year":"2007","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0300","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jaut.2018.01.007","article-title":"The immunobiology of mucosal-associated invariant T cell (MAIT) function in primary biliary cholangitis: Regulation by cholic acid-induced Interleukin-7","volume":"90","author":"Jiang","year":"2018","journal-title":"Journal of Autoimmunity"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0305","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/hep4.1478","article-title":"Farnesoid X receptor activation protects liver from ischemia\/reperfusion injury by up-regulating small heterodimer partner in kupffer cells","volume":"4","author":"Jin","year":"2020","journal-title":"Hepatology Communications"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0310","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1053\/gast.2002.33583","article-title":"Human organic anion transporting polypeptide 8 promoter is transactivated by the farnesoid X receptor\/bile acid receptor","volume":"122","author":"Jung","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0315","doi-asserted-by":"crossref","first-page":"9435","DOI":"10.1074\/jbc.M209706200","article-title":"A G protein-coupled receptor responsive to bile acids","volume":"278","author":"Kawamata","year":"2003","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0320","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.bbadis.2010.11.011","article-title":"Regulation of FXR transcriptional activity in health and disease: Emerging roles of FXR cofactors and post-translational modifications","volume":"1812","author":"Kemper","year":"2011","journal-title":"Biochimica et Biophysica Acta"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0325","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1002\/hep.30407","article-title":"Hepatic autophagy deficiency compromises farnesoid X receptor functionality and causes cholestatic injury","volume":"69","author":"Khambu","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0330","doi-asserted-by":"crossref","first-page":"184","DOI":"10.15252\/embj.201489527","article-title":"A dysregulated acetyl\/SUMO switch of FXR promotes hepatic inflammation in obesity","volume":"34","author":"Kim","year":"2015","journal-title":"The EMBO Journal"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0335","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1194\/jlr.M700330-JLR200","article-title":"Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine","volume":"48","author":"Kim","year":"2007","journal-title":"Journal of Lipid Research"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0340","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1093\/carcin\/bgl249","article-title":"Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice","volume":"28","author":"Kim","year":"2007","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0345","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1053\/gast.2002.33617","article-title":"Transporter-mediated bile acid uptake causes Ca2+-dependent cell death in rat pancreatic acinar cells","volume":"122","author":"Kim","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0350","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/hep.29199","article-title":"Hepatic FXR\/SHP axis modulates systemic glucose and fatty acid homeostasis in aged mice","volume":"66","author":"Kim","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0355","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.2337\/db17-1502","article-title":"Glucagon receptor signaling regulates energy metabolism via hepatic farnesoid X receptor and fibroblast growth factor 21","volume":"67","author":"Kim","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0360","doi-asserted-by":"crossref","first-page":"G295","DOI":"10.1152\/ajpgi.00134.2015","article-title":"Mice with hepatocyte-specific FXR deficiency are resistant to spontaneous but susceptible to cholic acid-induced hepatocarcinogenesis","volume":"310","author":"Kong","year":"2016","journal-title":"American Journal of Physiology. Gastrointestinal and Liver Physiology"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0365","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1002\/hep.29569","article-title":"A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis","volume":"67","author":"Kowdley","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0370","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jaut.2008.11.001","article-title":"Hepatic IL-17 responses in human and murine primary biliary cirrhosis","volume":"32","author":"Lan","year":"2009","journal-title":"Journal of Autoimmunity"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0375","doi-asserted-by":"crossref","first-page":"G476","DOI":"10.1152\/ajpgi.00430.2005","article-title":"The nuclear receptor for bile acids, FXR, transactivates human organic solute transporter-alpha and -beta genes","volume":"290","author":"Landrier","year":"2006","journal-title":"American Journal of Physiology. Gastrointestinal and Liver Physiology"},{"issue":"1206\u20131217","key":"10.1016\/j.pharmthera.2021.107867_bb0380","article-title":"Farnesoid X receptor protects hepatocytes from injury by repressing miR-199a-3p, which increases levels of LKB1","volume":"142","author":"Lee","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0385","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1210\/me.2010-0117","article-title":"Activation of the farnesoid X receptor provides protection against acetaminophen-induced hepatic toxicity","volume":"24","author":"Lee","year":"2010","journal-title":"Molecular Endocrinology"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0390","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature13961","article-title":"Nutrient-sensing nuclear receptors coordinate autophagy","volume":"516","author":"Lee","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0395","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/bjc.2011.37","article-title":"Farnesoid X receptor, overexpressed in pancreatic cancer with lymph node metastasis promotes cell migration and invasion","volume":"104","author":"Lee","year":"2011","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0400","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.apsb.2015.01.005","article-title":"Farnesoid X receptor, the bile acid sensing nuclear receptor, in liver regeneration","volume":"5","author":"Li","year":"2015","journal-title":"Acta Pharmaceutica Sinica B"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0405","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/cvr\/cvm016","article-title":"FXR-mediated regulation of eNOS expression in vascular endothelial cells","volume":"77","author":"Li","year":"2008","journal-title":"Cardiovascular Research"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0410","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1124\/mol.110.068247","article-title":"Roles of microRNA-29a in the antifibrotic effect of farnesoid X receptor in hepatic stellate cells","volume":"80","author":"Li","year":"2011","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0415","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1161\/ATVBAHA.113.302028","article-title":"Endothelin-1 overexpression exacerbates atherosclerosis and induces aortic aneurysms in apolipoprotein E knockout mice","volume":"33","author":"Li","year":"2013","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0420","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/hep.24107","article-title":"Overexpression of cholesterol 7\u03b1-hydroxylase promotes hepatic bile acid synthesis and secretion and maintains cholesterol homeostasis","volume":"53","author":"Li","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0425","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1161\/ATVBAHA.107.152694","article-title":"Farnesoid x receptor ligands inhibit vascular smooth muscle cell inflammation and migration","volume":"27","author":"Li","year":"2007","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0430","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1152\/physiolgenomics.00151.2012","article-title":"Nuclear receptor atlas of female mouse liver parenchymal, endothelial, and Kupffer cells","volume":"45","author":"Li","year":"2013","journal-title":"Physiological Genomics"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0435","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/hep.29815","article-title":"Farnesoid X receptor signaling activates the hepatic X-box binding protein 1 pathway in vitro and in mice","volume":"68","author":"Liu","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0440","first-page":"360","article-title":"Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells","author":"Ma","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0445","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1172\/JCI25604","article-title":"Farnesoid X receptor is essential for normal glucose homeostasis","volume":"116","author":"Ma","year":"2006","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0450","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jalz.2018.07.217","article-title":"Altered bile acid profile associates with cognitive impairment in Alzheimer's disease-An emerging role for gut microbiome","volume":"15","author":"MahmoudianDehkordi","year":"2019","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0455","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.apsb.2014.12.011","article-title":"Role of farnesoid X receptor and bile acids in alcoholic liver disease","volume":"5","author":"Manley","year":"2015","journal-title":"Acta Pharmaceutica Sinica B"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0460","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.redox.2014.08.007","article-title":"Farnesoid X receptor regulates forkhead Box O3a activation in ethanol-induced autophagy and hepatotoxicity","volume":"2","author":"Manley","year":"2014","journal-title":"Redox Biology"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0465","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1194\/jlr.M300369-JLR200","article-title":"Presence of protein-bound unconjugated bile acids in the cytoplasmic fraction of rat brain","volume":"45","author":"Mano","year":"2004","journal-title":"Journal of Lipid Research"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0470","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1681\/ASN.2016101123","article-title":"Farnesoid X receptor agonism protects against diabetic tubulopathy: Potential add-on therapy for diabetic nephropathy","volume":"28","author":"Marquardt","year":"2017","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0475","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.bbadis.2015.11.001","article-title":"Splenic dendritic cell involvement in FXR-mediated amelioration of DSS colitis","volume":"1862","author":"Massafra","year":"2016","journal-title":"Biochimica et Biophysica Acta"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0480","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1096\/fj.201600275R","article-title":"Effects of bile acids on neurological function and disease","volume":"30","author":"McMillin","year":"2016","journal-title":"The FASEB Journal"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0485","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3389\/fncel.2017.00191","article-title":"Bile acid-mediated sphingosine-1-phosphate receptor 2 signaling promotes neuroinflammation during hepatic encephalopathy in mice","volume":"11","author":"McMillin","year":"2017","journal-title":"Frontiers in Cellular Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0490","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jcmgh.2018.02.008","article-title":"FXR-mediated cortical cholesterol accumulation contributes to the pathogenesis of type A hepatic encephalopathy","volume":"6","author":"McMillin","year":"2018","journal-title":"Cellular and Molecular Gastroenterology"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0495","doi-asserted-by":"crossref","first-page":"6657","DOI":"10.4049\/jimmunol.0901347","article-title":"The bile acid sensor farnesoid X receptor is a modulator of liver immunity in a rodent model of acute hepatitis","volume":"183","author":"Mencarelli","year":"2009","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2021.107867_bb8000","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2017.00617","article-title":"Bile acid signaling pathways from the enterohepatic circulation to the central nervous system","volume":"11","author":"Mertens","year":"2017","journal-title":"Frontiers in Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0500","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1161\/CIRCRESAHA.109.212969","article-title":"Farnesoid X receptor activation prevents the development of vascular calcification in ApoE-\/- mice with chronic kidney disease","volume":"106","author":"Miyazaki-Anzai","year":"2010","journal-title":"Circulation Research"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0505","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.dld.2018.05.016","article-title":"Bile acids and FXR in functional gastrointestinal disorders","volume":"50","author":"Mosinska","year":"2018","journal-title":"Digestive and Liver Disease"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0510","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2013.05.042","article-title":"Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease","volume":"145","author":"Mudaliar","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0515","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.jhep.2014.12.034","article-title":"Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity","volume":"62","author":"Mueller","year":"2015","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0520","first-page":"501","article-title":"FDA rejects NASH drug","volume":"19","author":"Mullard","year":"2020","journal-title":"Nature Reviews Drug Discovery"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0525","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/hep.20295","article-title":"Bile acid-induced negative feedback regulation of the human ileal bile acid transporter","volume":"40","author":"Neimark","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0530","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0535","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmet.2019.05.007","article-title":"Modeling steatohepatitis in humans with pluripotent stem cell-derived organoids","volume":"30","author":"Ouchi","year":"2019","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0540","doi-asserted-by":"crossref","DOI":"10.3390\/metabo7020028","article-title":"Metabolomic profiling of bile acids in clinical and experimental samples of Alzheimer\u2019s disease","volume":"7","author":"Pan","year":"2017","journal-title":"Metabolites"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0545","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1126\/science.284.5418.1365","article-title":"Bile acids: Natural ligands for an orphan nuclear receptor","volume":"284","author":"Parks","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0550","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.tips.2018.03.001","article-title":"Macrophage-targeted therapeutics for metabolic disease","volume":"39","author":"Peterson","year":"2018","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0555","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jhep.2018.06.022","article-title":"The nuclear bile acid receptor FXR is a PKA- and FOXA2-sensitive activator of fasting hepatic gluconeogenesis","volume":"69","author":"Ploton","year":"2018","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0560","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1172\/JCI88893","article-title":"Nutrient-sensing nuclear receptors PPAR\u03b1 and FXR control liver energy balance","volume":"127","author":"Preidis","year":"2017","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0565","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/eurheartj\/ehs011","article-title":"Cardiomyocyte-expressed farnesoid-X-receptor is a novel apoptosis mediator and contributes to myocardial ischaemia\/reperfusion injury","volume":"34","author":"Pu","year":"2013","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0570","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1053\/j.gastro.2020.07.036","article-title":"FXR isoforms control different metabolic functions in liver cells via binding to specific DNA motifs","volume":"159","author":"Ramos Pittol","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0575","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jsbmb.2017.10.011","article-title":"Comparison of the composition of bile acids in bile of patients with adenocarcinoma of the pancreas and benign disease","volume":"174","author":"Rees","year":"2017","journal-title":"Journal of Steroid Biochemistry and Molecular Biology"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0580","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.bbadis.2010.01.002","article-title":"The bile acid sensor FXR regulates insulin transcription and secretion","volume":"1802","author":"Renga","year":"2010","journal-title":"Biochimica et Biophysica Acta"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0585","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.bbadis.2009.04.004","article-title":"Reciprocal regulation of the bile acid-activated receptor FXR and the interferon \u03b3-STAT-1 pathway in macrophages","volume":"1792","author":"Renga","year":"2009","journal-title":"Biochimica et Biophysica Acta"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0590","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1021\/jm7015864","article-title":"Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies","volume":"51","author":"Sato","year":"2008","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0595","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.cmet.2013.01.003","article-title":"Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-\u03b2-muricholic acid, a naturally occurring FXR antagonist","volume":"17","author":"Sayin","year":"2013","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0600","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.molimm.2006.04.021","article-title":"Nuclear receptors in human immune cells: Expression and correlations","volume":"44","author":"Schote","year":"2007","journal-title":"Molecular Immunology"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0605","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/hep.30810","article-title":"Direct and indirect effects of fibroblast growth factor (FGF) 15 and FGF19 on liver fibrosis development","volume":"71","author":"Schumacher","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0610","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature13949","article-title":"Transcriptional regulation of autophagy by an FXR-CREB axis","volume":"516","author":"Seok","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0615","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1021\/acsmedchemlett.8b00423","article-title":"Novel isoxazole derivatives with potent FXR agonistic activity prevent acetaminophen-induced liver injury","volume":"10","author":"Sepe","year":"2019","journal-title":"ACS Medicinal Chemistry Letters"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0620","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12974-020-01838-w","article-title":"Farnesoid X receptor knockout protects brain against ischemic injury through reducing neuronal apoptosis in mice","volume":"17","author":"Shan","year":"2020","journal-title":"Journal of Neuroinflammation"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0625","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0092-8674(00)00062-3","article-title":"Targeted disruption of the nuclear receptor FXR\/BAR impairs bile acid and lipid homeostasis","volume":"102","author":"Sinal","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0630","doi-asserted-by":"crossref","first-page":"G1245","DOI":"10.1152\/ajpgi.00439.2011","article-title":"Downregulation of nuclear receptor FXR is associated with multiple malignant clinicopathological characteristics in human hepatocellular carcinoma","volume":"303","author":"Su","year":"2012","journal-title":"American Journal of Physiology - Gastrointestinal and Liver Physiology"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0635","doi-asserted-by":"crossref","DOI":"10.1038\/s41575-020-00404-2","article-title":"The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer","author":"Sun","year":"2021","journal-title":"Nature Reviews. Gastroenterology & Hepatology"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0640","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1038\/s41591-018-0222-4","article-title":"Gut microbiota and intestinal FXR mediate the clinical benefits of metformin","volume":"24","author":"Sun","year":"2018","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0645","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1124\/dmd.120.000215","article-title":"The hypoglycemic effect of berberine and berberrubine involves modulation of intestinal farnesoid X receptor signaling pathway and inhibition of hepatic gluconeogenesis","volume":"49","author":"Sun","year":"2021","journal-title":"Drug Metabolism and Disposition"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0650","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1124\/mol.116.106617","article-title":"Orally administered berberine mdulates hepatic lpid mtabolism by atering mcrobial ble aid mtabolism and the itestinal FXR sgnaling pthway","volume":"91","author":"Sun","year":"2017","journal-title":"Molecular Pharmacology"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2021.107867_bb0655","doi-asserted-by":"crossref","first-page":"4523","DOI":"10.1073\/pnas.1006734107","article-title":"Systemic gut microbial modulation of bile acid metabolism in host tissue compartments","volume":"108","author":"Swann","year":"2011","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0660","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1074\/jbc.RA119.011913","article-title":"Bile acid sequestration reverses liver injury and prevents progression of nonalcoholic steatohepatitis in Western diet-fed mice","volume":"295","author":"Takahashi","year":"2020","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0665","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1002\/hep4.1263","article-title":"Role of farnesoid X receptor and bile acids in hepatic tumor development","volume":"2","author":"Takahashi","year":"2018","journal-title":"Hepatology Communications"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0670","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/toxsci\/kfx094","article-title":"Editor\u2019s Highlight: Farnesoid X receptor protects against low-dose carbon tetrachloride-induced liver injury through the taurocholate-JNK pathway","volume":"158","author":"Takahashi","year":"2017","journal-title":"Toxicological Sciences"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0675","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.pharmthera.2017.05.011","article-title":"Targeting nuclear receptors for the treatment of fatty liver disease","volume":"179","author":"Tanaka","year":"2017","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0680","doi-asserted-by":"crossref","first-page":"6251","DOI":"10.4049\/jimmunol.0803978","article-title":"The bile acid receptor FXR is a modulator of intestinal innate immunity","volume":"183","author":"Vavassori","year":"2009","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0685","doi-asserted-by":"crossref","first-page":"33453","DOI":"10.1038\/srep33453","article-title":"FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis","volume":"6","author":"Verbeke","year":"2016","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0690","doi-asserted-by":"crossref","first-page":"650","DOI":"10.3389\/fphys.2020.00650","article-title":"Bile Acid supplementation improves murine pancreatitis in association with the gut microbiota","volume":"11","author":"Wan","year":"2020","journal-title":"Frontiers in Physiology"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0695","doi-asserted-by":"crossref","first-page":"111949","DOI":"10.1016\/j.yexcr.2020.111949","article-title":"Farnesoid X receptor (FXR) activation induces the antioxidant protein metallothionein 1 expression in mouse liver","volume":"390","author":"Wang","year":"2020","journal-title":"Experimental Cell Research"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0700","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1097-2765(00)80348-2","article-title":"Endogenous bile acids are ligands for the nuclear receptor FXR\/BAR","volume":"3","author":"Wang","year":"1999","journal-title":"Molecular Cell"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0705","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ebiom.2018.10.028","article-title":"Noncanonical farnesoid X receptor signaling inhibits apoptosis and impedes liver fibrosis","volume":"37","author":"Wang","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0710","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1080\/13543776.2018.1527906","article-title":"FXR modulators for enterohepatic and metabolic diseases","volume":"28","author":"Wang","year":"2018","journal-title":"Expert Opinion on Therapeutic Patents"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0715","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.2337\/db10-0019","article-title":"Diabetic nephropathy is accelerated by farnesoid X receptor deficiency and inhibited by farnesoid X receptor activation in a type 1 diabetes model","volume":"59","author":"Wang","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0720","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1681\/ASN.2017020222","article-title":"FXR\/TGR5 dual agonist prevents progression of nephropathy in diabetes and obesity","volume":"29","author":"Wang","year":"2018","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0725","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1002\/hep.22519","article-title":"Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response","volume":"48","author":"Wang","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0730","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1056\/NEJMra1600561","article-title":"Hepatic encephalopathy","volume":"375","author":"Wijdicks","year":"2016","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0735","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1111\/all.12019","article-title":"Ursodeoxycholic acid suppresses eosinophilic airway inflammation by inhibiting the function of dendritic cells through the nuclear farnesoid X receptor","volume":"67","author":"Willart","year":"2012","journal-title":"Allergy"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0740","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12964-020-0525-1","article-title":"FXR-mediated inhibition of autophagy contributes to FA-induced TG accumulation and accordingly reduces FA-induced lipotoxicity","volume":"18","author":"Wu","year":"2020","journal-title":"Cell Communication and Signaling: CCS"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0745","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.bbrc.2013.11.057","article-title":"Activation of farnesoid X receptor attenuates hepatic injury in a murine model of alcoholic liver disease","volume":"443","author":"Wu","year":"2014","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0750","doi-asserted-by":"crossref","first-page":"613","DOI":"10.2337\/db16-0663","article-title":"An intestinal farnesoid X receptor-ceramide signaling axis modulates hepatic gluconeogenesis in mice","volume":"66","author":"Xie","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0755","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ebiom.2018.10.030","article-title":"Dysregulated bile acid signaling contributes to the neurological impairment in murine models of acute and chronic liver failure","volume":"37","author":"Xie","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0760","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1002\/1873-3468.12782","article-title":"A rapid administration of GW4064 inhibits the NLRP3 inflammasome activation independent of farnesoid X receptor agonism","volume":"591","author":"Xie","year":"2017","journal-title":"FEBS Letters"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0765","doi-asserted-by":"crossref","first-page":"18751","DOI":"10.1038\/srep18751","article-title":"Farnesoid X receptor activation promotes cell proliferation via PDK4-controlled metabolic reprogramming","volume":"6","author":"Xie","year":"2016","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0770","doi-asserted-by":"crossref","first-page":"5600","DOI":"10.1073\/pnas.1803945115","article-title":"Farnesoid X receptor is essential for the survival of renal medullary collecting duct cells under hypertonic stress","volume":"115","author":"Xu","year":"2018","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0775","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.taap.2016.12.001","article-title":"Dihydroartemisinin protects against alcoholic liver injury through alleviating hepatocyte steatosis in a farnesoid X receptor-dependent manner","volume":"315","author":"Xu","year":"2017","journal-title":"Toxicology and Applied Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0780","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.metabol.2018.03.016","article-title":"HS218 as an FXR antagonist suppresses gluconeogenesis by inhibiting FXR binding to PGC-1\u03b1 promoter","volume":"85","author":"Xu","year":"2018","journal-title":"Metabolism"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0785","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13005","article-title":"Farnesoid X receptor promotes renal ischaemia-reperfusion injury by inducing tubular epithelial cell apoptosis","volume":"54","author":"Xu","year":"2021","journal-title":"Cell Proliferation"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0790","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/j.cellsig.2012.04.015","article-title":"FXR ligands protect against hepatocellular inflammation via SOCS3 induction","volume":"24","author":"Xu","year":"2012","journal-title":"Cell Signaling"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0795","doi-asserted-by":"crossref","DOI":"10.1093\/toxsci\/kfab027","article-title":"FXR-deoxycholic acid-TNF\u03b1 axis modulates acetaminophen-induced hepatotoxicity","author":"Yan","year":"2021","journal-title":"Toxicological Sciences"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0800","doi-asserted-by":"crossref","first-page":"6115","DOI":"10.1038\/ncomms7115","article-title":"Small heterodimer partner interacts with NLRP3 and negatively regulates activation of the NLRP3 inflammasome","volume":"6","author":"Yang","year":"2015","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0805","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1158\/0008-5472.CAN-06-1078","article-title":"Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor","volume":"67","author":"Yang","year":"2007","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0810","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s12072-010-9202-6","article-title":"Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease","volume":"4","author":"Yang","year":"2010","journal-title":"Hepatology International"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0815","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1002\/jcp.25742","article-title":"TUDCA: An agonist of the bile acid receptor GPBAR1\/TGR5 with anti-inflammatory effects in microglial cells","volume":"232","author":"Yanguas-Casas","year":"2017","journal-title":"Journal of Cellular Physiology"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0820","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: Interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"The Lancet"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0825","doi-asserted-by":"crossref","first-page":"31441","DOI":"10.1074\/jbc.M200474200","article-title":"Lithocholic acid decreases expression of bile salt export pump through farnesoid X receptor antagonist activity","volume":"277","author":"Yu","year":"2002","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0830","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.taap.2016.11.006","article-title":"Obeticholic acid protects against carbon tetrachloride-induced acute liver injury and inflammation","volume":"314","author":"Zhang","year":"2017","journal-title":"Toxicology and Applied Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0835","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.dld.2018.04.009","article-title":"FXR deletion in hepatocytes does not affect the severity of alcoholic liver disease in mice","volume":"50","author":"Zhang","year":"2018","journal-title":"Digestive and Liver Disease"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0840","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/cvr\/cvm068","article-title":"FXR-mediated regulation of angiotensin type 2 receptor expression in vascular smooth muscle cells","volume":"77","author":"Zhang","year":"2008","journal-title":"Cardiovascular Research"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0845","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1073\/pnas.1323977111","article-title":"Farnesoid X receptor (FXR) gene deficiency impairs urine concentration in mice","volume":"111","author":"Zhang","year":"2014","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0850","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.biopha.2017.10.153","article-title":"Protective effect of dioscin against thioacetamide-induced acute liver injury via FXR\/AMPK signaling pathway in vivo","volume":"97","author":"Zheng","year":"2018","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0855","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s41467-019-14138-6","article-title":"SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis","volume":"11","author":"Zhou","year":"2020","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0860","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.apsb.2018.11.004","article-title":"Combined obeticholic acid and apoptosis inhibitor treatment alleviates liver fibrosis","volume":"9","author":"Zhou","year":"2019","journal-title":"Acta Pharmaceutica Sinica B"},{"key":"10.1016\/j.pharmthera.2021.107867_bb0865","doi-asserted-by":"crossref","first-page":"17027","DOI":"10.1038\/cddiscovery.2017.27","article-title":"The bile acid receptor FXR attenuates acinar cell autophagy in chronic pancreatitis","volume":"3","author":"Zhou","year":"2017","journal-title":"Cell Death Discovery"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725821000693?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725821000693?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:18:27Z","timestamp":1759011507000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725821000693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":174,"alternative-id":["S0163725821000693"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2021.107867","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The pathophysiological function of non-gastrointestinal farnesoid X receptor","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2021.107867","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107867"}}